Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

CKS1 Germ Line Exclusion Is Essential for the Transition from Meiosis to Early Embryonic Development.

Ellederova Z, Del Rincon S, Koncicka M, Susor A, Kubelka M, Sun D, Spruck C.

Mol Cell Biol. 2019 Jun 13;39(13). pii: e00590-18. doi: 10.1128/MCB.00590-18. Print 2019 Jul 1.

PMID:
30988159
2.

CKS protein overexpression renders tumors susceptible to a chemotherapeutic strategy that protects normal tissues.

Tat J, Loriot C, Henze M, Spruck C, Felding BH, Reed SI.

Oncotarget. 2017 Dec 4;8(70):114911-114923. doi: 10.18632/oncotarget.22931. eCollection 2017 Dec 29.

3.

F-box proteins in epigenetic regulation of cancer.

Shen J, Spruck C.

Oncotarget. 2017 Nov 16;8(66):110650-110655. doi: 10.18632/oncotarget.22469. eCollection 2017 Dec 15. Review.

4.

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.

Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, Rosén G, Čančer M, Hutter S, Sundström A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Cho YJ, Pfister SM, Kool M, Korshunov A, Swartling FJ, Sangfelt O.

EMBO J. 2016 Oct 17;35(20):2192-2212. Epub 2016 Sep 13.

5.

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3.

Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, Larsson O, Muller WJ, Miller WH, Sonenberg N.

Oncogene. 2015 Apr 16;34(16):2032-42. doi: 10.1038/onc.2014.146. Epub 2014 Jun 9.

6.

Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints.

del Rincón SV, Widschwendter M, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed SI, Spruck C.

Oncogene. 2015 Apr 9;34(15):1961-7. doi: 10.1038/onc.2014.137. Epub 2014 May 26.

7.

PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer.

Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, Widschwendter M, Spruck C.

Cancer Res. 2014 Apr 1;74(7):2006-14. doi: 10.1158/0008-5472.CAN-13-1263. Epub 2014 Feb 7.

8.

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Viñals F, Bhaskaran N, Zakaria SM, Rahmanto AS, Grotegut S, Nielsen ML, Szigyarto CA, Sun D, Lerner M, Navani S, Widschwendter M, Uhlén M, Jirström K, Pontén F, Wohlschlegel J, Grandér D, Spruck C, Larsson LG, Sangfelt O.

EMBO Mol Med. 2013 Jul;5(7):1067-86. doi: 10.1002/emmm.201202341. Epub 2013 Jun 14.

9.

Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response.

López-Díaz FJ, Gascard P, Balakrishnan SK, Zhao J, Del Rincon SV, Spruck C, Tlsty TD, Emerson BM.

Mol Cell. 2013 May 23;50(4):552-64. doi: 10.1016/j.molcel.2013.04.029.

10.

miR-27a regulation of SCF(Fbw7) in cell division control and cancer.

Spruck C.

Cell Cycle. 2011 Oct 1;10(19):3232-3. doi: 10.4161/cc.10.19.17125. Epub 2011 Oct 1. No abstract available.

PMID:
21946522
11.

Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.

Liberal V, Martinsson-Ahlzén HS, Liberal J, Spruck CH, Widschwendter M, McGowan CH, Reed SI.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2754-9. doi: 10.1073/pnas.1102434108. Epub 2011 Jun 22.

12.

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O.

Breast Cancer Res. 2010;12(6):R105. doi: 10.1186/bcr2788. Epub 2010 Dec 1.

13.

Development and validation of a method for profiling post-translational modification activities using protein microarrays.

Del Rincón SV, Rogers J, Widschwendter M, Sun D, Sieburg HB, Spruck C.

PLoS One. 2010 Jun 28;5(6):e11332. doi: 10.1371/journal.pone.0011332.

14.

Control of iron homeostasis by an iron-regulated ubiquitin ligase.

Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, Bhaskaran N, Persson A, Uhlen M, Sangfelt O, Spruck C, Leibold EA, Wohlschlegel JA.

Science. 2009 Oct 30;326(5953):718-21. doi: 10.1126/science.1176333. Epub 2009 Sep 17.

15.

SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.

Klotz K, Cepeda D, Tan Y, Sun D, Sangfelt O, Spruck C.

Exp Cell Res. 2009 Jul 1;315(11):1832-9. doi: 10.1016/j.yexcr.2008.11.017. Epub 2008 Dec 3.

PMID:
19084516
16.

Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells.

Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, Chaves SR, Spruck CH, Reed SI.

Mol Cell Biol. 2008 Sep;28(18):5698-709. doi: 10.1128/MCB.01833-07. Epub 2008 Jul 14.

17.

The Fbxw7/hCdc4 tumor suppressor in human cancer.

Tan Y, Sangfelt O, Spruck C.

Cancer Lett. 2008 Nov 18;271(1):1-12. doi: 10.1016/j.canlet.2008.04.036. Epub 2008 Jun 9. Review.

PMID:
18541364
18.

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C.

Cancer Res. 2007 Oct 1;67(19):9006-12. Erratum in: Cancer Res. 2008 Feb 15;68(4):1245. Dofou, Dimitra [corrected to Dafou, Dimitra].

19.

The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.

Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O.

Cancer Res. 2007 Jun 15;67(12):5611-6. Erratum in: Cancer Res. 2008 Mar 15;68(6):2051. Akhondi, Shahab [corrected to Akhoondi, Shahab].

20.

Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.

Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, Chung L, Yang C, Spruck C, Boyd K, Reed SI, Cleveland JL.

EMBO J. 2007 May 16;26(10):2562-74. Epub 2007 Apr 26.

21.

Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer.

Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI.

Cancer Res. 2006 Jul 15;66(14):7355-60.

22.

Cyclin E dysregulation and chromosomal instability in endometrial cancer.

Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Müller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M.

Oncogene. 2004 May 20;23(23):4187-92.

PMID:
15048079
23.

Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.

Ekholm-Reed S, Spruck CH, Sangfelt O, van Drogen F, Mueller-Holzner E, Widschwendter M, Zetterberg A, Reed SI.

Cancer Res. 2004 Feb 1;64(3):795-800. Erratum in: Cancer Res. 2004 Apr 15;64(8):2939. Reed, Susanna Ekholm [corrected to Reed-Ekholm, Susanna].

24.

Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis.

Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ, Reed SI.

Science. 2003 Apr 25;300(5619):647-50.

25.

Seek and destroy: SCF ubiquitin ligases in mammalian cell cycle control.

Spruck CH, Strohmaier HM.

Cell Cycle. 2002 Jul-Aug;1(4):250-4. Review.

PMID:
12429941
26.

hCDC4 gene mutations in endometrial cancer.

Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI.

Cancer Res. 2002 Aug 15;62(16):4535-9.

27.

Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI.

Nature. 2001 Sep 20;413(6853):316-22.

PMID:
11565034
28.

A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.

Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI.

Mol Cell. 2001 Mar;7(3):639-50.

29.

Deregulated cyclin E induces chromosome instability.

Spruck CH, Won KA, Reed SI.

Nature. 1999 Sep 16;401(6750):297-300.

PMID:
10499591
30.
31.

Evidence for multiclonality in multicentric Kaposi's sarcoma.

Gill PS, Tsai YC, Rao AP, Spruck CH 3rd, Zheng T, Harrington WA Jr, Cheung T, Nathwani B, Jones PA.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8257-61.

32.

Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC.

Van Tornout JM, Spruck CH 3rd, Shibata A, Schmutte C, Gonzalez-Zulueta M, Nichols PW, Chandrasoma PT, Yu MC, Jones PA.

Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):493-7.

33.

Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR.

Gonzalgo ML, Liang G, Spruck CH 3rd, Zingg JM, Rideout WM 3rd, Jones PA.

Cancer Res. 1997 Feb 15;57(4):594-9.

34.

Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.

Simoneau AR, Spruck CH 3rd, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA.

Cancer Res. 1996 Nov 1;56(21):5039-43.

35.

High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.

Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH 3rd, Busch C, Shamaa M, El-Baz M, Nichols PW, Gonzalgo ML, Elbaz M [corrected to El-Baz M], et al.

J Natl Cancer Inst. 1995 Sep 20;87(18):1383-93. Erratum in: J Natl Cancer Inst 1995 Dec 6;87(23):1807.

PMID:
7658499
36.

Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium.

Tsai YC, Simoneau AR, Spruck CH 3rd, Nichols PW, Steven K, Buckley JD, Jones PA.

J Urol. 1995 May;153(5):1697-700.

PMID:
7715013
37.

Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation.

Rideout WM 3rd, Eversole-Cire P, Spruck CH 3rd, Hustad CM, Coetzee GA, Gonzales FA, Jones PA.

Mol Cell Biol. 1994 Sep;14(9):6143-52.

38.

p16 gene in uncultured tumours.

Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA.

Nature. 1994 Jul 21;370(6486):183-4. No abstract available.

PMID:
8028660
39.

Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan.

Shibata A, Ohneseit PF, Tsai YC, Spruck CH 3rd, Nichols PW, Chiang HS, Lai MK, Jones PA.

Carcinogenesis. 1994 Jun;15(6):1085-7.

PMID:
8020137
40.

Two molecular pathways to transitional cell carcinoma of the bladder.

Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R, et al.

Cancer Res. 1994 Feb 1;54(3):784-8.

41.

Microsatellite instability in bladder cancer.

Gonzalez-Zulueta M, Ruppert JM, Tokino K, Tsai YC, Spruck CH 3rd, Miyao N, Nichols PW, Hermann GG, Horn T, Steven K, et al.

Cancer Res. 1993 Dec 1;53(23):5620-3.

42.

p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ.

Am J Pathol. 1993 Nov;143(5):1389-97.

43.

Role of chromosome 9 in human bladder cancer.

Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH 3rd, Gonzalez-Zulueta M, Nichols PW, Skinner DG, Jones PA.

Cancer Res. 1993 Sep 1;53(17):4066-70.

44.

Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

Spruck CH 3rd, Rideout WM 3rd, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, et al.

Cancer Res. 1993 Mar 1;53(5):1162-6. Erratum in: Cancer Res 1993 May 15;53(10 Suppl):2427.

45.

DNA methylation and cancer.

Spruck CH 3rd, Rideout WM 3rd, Jones PA.

EXS. 1993;64:487-509. Review. No abstract available.

PMID:
8418957
46.

Absence of p53 gene mutations in primary nasopharyngeal carcinomas.

Spruck CH 3rd, Tsai YC, Huang DP, Yang AS, Rideout WM 3rd, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC, Jones PA.

Cancer Res. 1992 Sep 1;52(17):4787-90.

47.

Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction.

Shibata D, Hawes D, Li ZH, Hernandez AM, Spruck CH, Nichols PW.

Am J Pathol. 1992 Sep;141(3):539-43.

48.

Methylation, mutation and cancer.

Jones PA, Rideout WM 3rd, Shen JC, Spruck CH, Tsai YC.

Bioessays. 1992 Jan;14(1):33-6. Review.

PMID:
1546979
49.

5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene.

Rideout WM 3rd, Coetzee GA, Olumi AF, Spruck CH, Jones PA.

Princess Takamatsu Symp. 1991;22:207-19. Review.

PMID:
1844242
50.

Depression of peripheral lymph node lymphocyte traffic in sheep following central venous allogeneic whole-blood transfusion.

Moore TC, Spruck CH, Lami JL, Ghaly A, Totz M, Said SI.

Transplantation. 1990 Apr;49(4):838-43. No abstract available.

PMID:
1970202

Supplemental Content

Loading ...
Support Center